DataArt Joins Biotechnology Association BIO Deutschland
Global technology consultancy DataArt announced today that it has joined BIO Deutschland, Germany's biotechnology industry association.
BIO Deutschland is one of the most influential biotech associations in Europe, established to support and promote the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 285 members and is active in a broad range of events that aim to provide biotechnology with a platform for discussion and interaction.
With an established Life Sciences Practice and dedicated R&D group, DataArt has accumulated extensive knowledge and deep expertise in building cutting-edge technology solutions in drug discovery and clinical trials. DataArt’s clients include prominent life sciences companies, such as Charles River Laboratories, Novaseek Research, PSI CRO, and Cancer Research UK. Within the BIO Deutschland, DataArt’s team has joined the Bio-IT, Big Data & E-Health working group.
“Joining BIO Deutschland is a tremendous opportunity for DataArt, to share our experience, engage with other industry players, and collaborate on resolving challenges,” said Daniel Piekarz, Head of DataArt’s Healthcare and Life Sciences Practice. “We’re particularly excited to join the working group dedicated to Bio-IT, Big Data & E-Health as this is our area of expertise and we look forward to helping move the industry forward.”
This article has been republished from materials provided by DataArt. Note: material may have been edited for length and content. For further information, please contact the cited source.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE